Compositions and Methods for Treatment of Cancer
AssigneeThe Trustees of the University of Pennsylvania
InventorsCarl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
Claims28
A human memory T cell comprising a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the human memory T cell is of a human having cancer.
A human memory T cell comprising a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the human memory T cell is of a human having cancer.
A persisting population of human T cells comprising a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the persisting population of T cells are of a human having cancer.
A persisting population of human T cells comprising a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the persisting population of T cells are of a human having cancer.
Dependencies are inferred from the claim text.